You are here: Home » Markets » News
Business Standard

Markets gone 'rogue' on coronavirus vaccine news face tough questions

Concerns about US fiscal stimulus, the transition of power to President-elect Joe Biden and surging virus cases also came back to the fore

Topics
stock markets | Coronavirus Vaccine

Joanna Ossinger | Bloomberg 

Coronavirus, vaccine, covid, drugs, clinical trials
The pandemic continues to escalate in the US, Europe, and elsewhere, with global cases now past 50 million

After a frenzy of vaccine optimism lifted global stocks to a record and sent havens into a tailspin, some strategists said the moves may have gone too far and tough questions remain unanswered. that the inoculation developed by Pfizer Inc. and BioNTech SE was more than 90 per cent effective in preventing Covid-19 infections sparked a surge of bets Monday on stocks such as cruise operators and airlines that wilted amid the pandemic.

Traditional refuges such as Treasuries, gold, and the yen slumped. But experts said the shot still has hurdles to clear, adding questions about its production, distribution and performance remain unanswered.

That tempered the euphoric earlier embrace of a potential path out of the health crisis. Concerns about US fiscal stimulus, the transition of power to President-elect Joe Biden and surging virus cases also came back to the fore. Monday’s vaccine was a positive and profound shock that “catalyzed a rogue wave of rotational optimism across global bond curves and risk-assets alike,” Edward Acton, rates strategist at Citigroup, wrote in an email. However, he added “there’s a great deficit of information we’re facing when analyzing a post-vaccine landscape — with plenty of room for disappointment.” A successful vaccine would shake up the prospects for the global economy.

Yet some forecasters remain cautious about changing their outlooks without clarity on how quickly a shot can be rolled out. The pandemic continues to escalate in the US, Europe, and elsewhere, with global cases now past 50 million. While were surprised by the efficacy of the Pfizer inoculation, the “challenge from here is looking through rising virus cases, slowing data and perhaps less stimulus until a vaccine can be widely distributed in mid-2021,” Stuart Kaiser, equity-derivatives strategist at UBS Securities, said in an email.

ALSO READ: Bull run continues: Sensex rises 680 points, Nifty settles at 12,631

The S&P 500 index closed at a two-month high on Monday, while the Nasdaq 100 index fell. Investors rotated out of defensive technology names into shares that would benefit if the pandemic ebbs.


chart

Principal Global Investors Chief Strategist Seema Shah wrote in a note that “market sentiment may be in the early stages of a burst of positive energy.” Value shares — stocks trading at lower multiples to profits or book value — jumped globally. JPMorgan Chase & Co. strategist Marko Kolanovic said the vaccine buttresses the case for the value rotation to endure. Jim Vogel of FHN Financial said the reaction in bonds looked “appropriate,” while stocks seem “slightly ahead of themselves.” Sundial Capital Research Inc.’s Jason Goepfert noted that bursts of equity gains such as in the past week can often see a pullback as the moves are digested. The vaccine-sparked global stock rally stalled Tuesday and havens such as gold and the yen clawed back some of Monday’s losses. S&P 500 futures slid 0.7 per cent per cent of 2:55 p.m. in Tokyo, erasing the gains sparked by the Pfizer release.

Progress toward an inoculation could also have an impact on the timing and scope of fresh spending on US pandemic relief, according to Michael Purves, chief executive officer at Tallbacken Capital Advisors LLC.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, November 10 2020. 22:17 IST
RECOMMENDED FOR YOU
.